BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE: BLGV) (OTCQB: BLGVF)
(“
Belgravia” or the “
Company”) is
pleased to provide the following corporate update on a number of
key strategic initiatives as well as forward progress on recently
announced projects:
Belgravia holds various assets including, but not
limited to, publicly-traded investments, private holdings, a
mining/water royalty and certain fixed income instruments. The
focus in 2018 was generally to be a passive-minority investor in
various industries and to provide management services which
generated income to Belgravia. The current focus in 2019 is to
acquire cash flow positive operating assets in either the cannabis,
gaming or pharmaceutical sectors. The Company intends to dedicate
its cash and other resources to the growth and development of its
fully-owned operating subsidiary. Belgravia believes this is the
best use of the Company’s capital, as it provides the greatest
upside potential for shareholder returns.
During Q1 of 2019 Belgravia reviewed dozens of
opportunities for an acquisition. Currently the Company is actively
doing its due diligence with specific targets to ensure this
creates shareholder value. With a current positive working capital
position, Belgravia is able to execute this plan without any
requirements for additional capital at this time. The terms will be
announced once a definitive agreement is in place.
Belgravia Subsidiary:
Belgravia Dermatology
A dermatology research subsidiary of Belgravia has
converted into a 7.9% ownership of GPCR Pharmaceuticals, Inc., a
private company focused on cannabinoid formulations for the
targeted delivery of dermatological pharmaceuticals. GPCR’s mandate
is to concentrate on prescription-based pharmaceuticals which will
require the completion of standard-phased development for
ethic-based drugs.
Belgravia Holdings:
Reciprocity Corp.
As previously announced on September 20, 2018,
Belgravia sought to enter the gaming industry. The Company has
since acquired 779,590 common shares (or 3.6% ownership) of
Reciprocity Corp., a premier global e-Sports organization.
Weekend Unlimited (CSE:POT)
In 2018, Belgravia invested in R&D Pharma, a
lifestyle cannabis company. The Company’s ownership has converted
into 7,682,795 common shares and 2,195,084 preferred shares of
Weekend Unlimited (CSE: POT) (“Weekend”). The
preferred shares of Weekend are convertible into common shares at
$0.35 per share for two years. In addition to its equity interest
in Weekend, Belgravia is owed $63,000 by R&D Pharma which we
expect and intend to recover.
Zonetail Inc. (TSXV: ZONE)
Belgravia owns 4,749,999 shares (or 7% ownership)
and 1,905,555 warrants of Zonetail Inc. In addition, Belgravia has
to date received management services fees of $325,000 and is owed a
further $325,000 under a short-term bridge loan agreement with
Zonetail. A consultant of Belgravia which provided key strategic
business development initiatives is owed $70,000.
Tartisan (CSE: TN)
In 2018 Belgravia commenced an action against
Tartisan and its CEO, Mark Appleby. On April 24, 2019 Mr. Appleby
was in discoveries. Representing Belgravia was Mr. Joe Groia, of
Groia & Company. Belgravia is seeking monetary damages of
$750,000 in the law suit together with other relief. Belgravia is
very confident in the final outcome of this law suit.
A full list of the Company’s holdings can be found
in the year end financials and Q1 financials which will be
announced prior to May 30th.
Water and Mining Royalty
Belgravia expects to provide an update in Q2 on the
status of the current mining royalty as well as the efforts to sell
the water from its water royalty interest, both located in New
Mexico, USA. As a result of existing confidentiality terms
Belgravia is prevented from providing fuller details of the
royalties except to say the Company has engaged a third party to
sell its water rights. Belgravia obtained both the mining and water
royalties in connection with its sale of IC Potash (USA) (which
owned the Ochoa Project) to its former partner Cartesian Capital of
New York. Water is in great demand by the fracturing business of
oil and gas companies in east New Mexico and West Texas. Water
wells WS-01 and WS-02 have been drilled and are available for
use.
Warrant Amendment
Belgravia intends to modify the terms of certain
share purchase warrants set to expire May 10, 2019 (the
“Warrants”). Of this series, 121,430,000 are held
by non-insiders and are exercisable at $0.06. In accordance with
the policies of the Canadian Securities Exchange, the terms of only
9.37% of the warrants held by insiders are being amended. The date
of expiration of the Warrants will be extended to July 10,
2019.
The expiration of all Warrants will be accelerated
to 30 days if the share price reaches or exceeds $0.08 for ten
consecutive trading days (“Acceleration Trigger”),
with such 30-day period starting seven-days after the Acceleration
Trigger. All other terms of the Warrants remain unchanged.
About Belgravia
Belgravia Capital International Inc. is focused on
three core business divisions: Incubator, Investments, and Royalty
& Management Services. The three divisions of Belgravia are
high risk business ventures and expose shareholders to financial
risks. The Incubator division provides capital to support the
development of early stage companies in the Biotech/Healthcare,
Technology, Resources and Medical sectors. Belgravia Holdings, the
Investments division, invests in various private and public
companies with a focus on value. Belgravia Royalty & Management
Services has a royalty and fee income model. Further, the cash and
investment asset base provide capital to support expansion on a
selective basis.
Forward-Looking Statements
Certain information set forth in this news release
may contain forward-looking statements that involve substantial
known and unknown risks and uncertainties and other factors which
may cause the actual results, performance or achievements of the
Company to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Forward-looking statements include
statements that use forward-looking terminology such as “may”,
“will”, “expect”, “anticipate”, “believe”, “continue”, “potential”
or the negative thereof or other variations thereof or comparable
terminology. Such forward-looking statements include, without
limitation, statements regarding planned investment activities
& related returns, the timing for completion of research and
development activities, the potential value of royalties, and other
statements that are not historical facts. These forward-looking
statements are subject to numerous risks and uncertainties, certain
of which are beyond the control of the Company, including, but not
limited to, changes in market trends, the completion, results and
timing of research undertaken by the Company, risks associated with
resource assets, the impact of general economic conditions,
commodity prices, industry conditions, dependence upon regulatory,
environmental, and governmental approvals, and the uncertainty of
obtaining additional financing. Readers are cautioned that the
assumptions used in the preparation of such information, although
considered reasonable at the time of preparation, may prove to be
imprecise and, as such, undue reliance should not be placed on
forward-looking statements.
For More Information, Please
Contact:
Mehdi Azodi, President & CEOBelgravia Capital
International Inc.(416) 779-3268mazodi@blgv.ca
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Dec 2023 to Dec 2024